STAT

Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

In the latest episode of our #biotech #podcast, "The Readout LOUD," we cover a fascinating #CRISPR debate and one company's efforts to craft pills that can do what has thus…

Who gets to “play God”? Can old technologies learn new tricks? And what does “drug price” even mean?

We discuss all

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks